Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53

Authors: Ralf Wiedemuth, Barbara Klink, Katrin Töpfer, Evelin Schröck, Gabriele Schackert, Masaaki Tatsuka, Achim Temme

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Survivin, a member of the inhibitor of apoptosis (IAP) gene family, has a dual role in mitosis and in apoptosis. It is abundantly expressed in every human tumor, compared with normal tissues. During mitosis Survivin assembles with the chromosomal passenger complex and regulates chromosomal segregation. Here, we aim to explore whether interference with the mitotic function of Survivin is linked to p53-mediated G1 cell cycle arrest and affects chromosomal stability.

Methods

In this study, we used HCT116, SBC-2, and U87-MG and generated corresponding isogenic p53-deficient cells. Retroviral vectors were used to stably knockdown Survivin. The resulting phenotype, in particular the mechanisms of cell cycle arrest and of initiation of aneuploidy, were investigated by Western Blot analysis, confocal laser scan microscopy, proliferation assays, spectral karyotyping and RNAi.

Results

In all cell lines Survivin-RNAi did not induce instant apoptosis but caused polyplodization irrespective of p53 status. Strikingly, polyploidization after knockdown of Survivin resulted in merotelic kinetochore spindle assemblies, γH2AX-foci, and DNA damage response (DDR), which was accompanied by a transient p53-mediated G1-arrest. That p53 wild type cells specifically arrest due to DNA damage was shown by simultaneous inhibition of ATM and DNA-PK, which abolished induction of p21waf/cip. Cytogenetic analysis revealed chromosomal aberrations indicative for DNA double strand break repair by the mechanism of non-homologous end joining (NHEJ), only in Survivin-depleted cells.

Conclusion

Our findings suggest that Survivin plays an essential role in proper amphitelic kinetochore-spindle assembly and that constraining Survivin’s mitotic function results in polyploidy and aneuploidy which cannot be controlled by p53. Therefore, Survivin critically safeguards chromosomal stability independently from p53.
Appendix
Available only for authorised users
Literature
1.
Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3: 917-921. 10.1038/nm0897-917CrossRefPubMed
2.
Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Zhang W, Zhang X, Zhou W, Haluska FG, Jen J, Sukumar S: Analysis of human transcriptomes. Nat Genet. 1999, 23: 387-388.CrossRefPubMed
3.
Crook NE, Clem RJ, Miller LK: An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol. 1993, 67: 2168-2174.PubMedCentralPubMed
4.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396: 580-584. 10.1038/25141CrossRefPubMed
5.
Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1999, 1: 461-466. 10.1038/70242CrossRefPubMed
6.
O’Connor DS, Wall NR, Porter AC, Altieri DC: A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002, 2: 43-54. 10.1016/S1535-6108(02)00084-3CrossRefPubMed
7.
O’Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000, 156: 393-398. 10.1016/S0002-9440(10)64742-6PubMedCentralCrossRefPubMed
8.
Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and −7. Biochemistry. 2001, 40: 1117-1123. 10.1021/bi001603qCrossRefPubMed
9.
Song Z, Yao X, Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003, 278: 23130-23140. 10.1074/jbc.M300957200CrossRefPubMed
10.
Carmena M, Wheelock M, Funabiki H, Earnshaw WC: The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol. 2012, 13: 789-803. 10.1038/nrm3474PubMedCentralCrossRefPubMed
11.
Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH: Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000, 10: 1319-1328. 10.1016/S0960-9822(00)00769-7CrossRefPubMed
12.
Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC: INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol. 2001, 11: 886-890. 10.1016/S0960-9822(01)00238-XCrossRefPubMed
13.
Gassmann R, Carvalho A, Henzing AJ, Ruchaud S, Hudson DF, Honda R, Nigg EA, Gerloff DL, Earnshaw WC: Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol. 2004, 166: 179-191. 10.1083/jcb.200404001PubMedCentralCrossRefPubMed
14.
Ruchaud S, Carmena M, Earnshaw WC: The chromosomal passenger complex: one for all and all for one. Cell. 2007, 131: 230-231. 10.1016/j.cell.2007.10.002CrossRefPubMed
15.
Lens SM, Rodriguez JA, Vader G, Span SW, Giaccone G, Medema RH: Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell. 2006, 17: 1897-1909. 10.1091/mbc.E05-08-0727PubMedCentralCrossRefPubMed
16.
Vader G, Cruijsen CW, van HT, Vromans MJ, Medema RH, Lens SM: The chromosomal passenger complex controls spindle checkpoint function independent from its role in correcting microtubule kinetochore interactions. Mol Biol Cell. 2007, 18: 4553-4564. 10.1091/mbc.E07-04-0328PubMedCentralCrossRefPubMed
17.
Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van MJ, Rieder CL, Peters JM: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol. 2003, 161: 281-294. 10.1083/jcb.200208092PubMedCentralCrossRefPubMed
18.
Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci. 2003, 116: 2987-2998. 10.1242/jcs.00612CrossRefPubMed
19.
Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH: Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J. 2003, 22: 2934-2947. 10.1093/emboj/cdg307PubMedCentralCrossRefPubMed
20.
Lampson MA, Renduchitala K, Khodjakov A, Kapoor TM: Correcting improper chromosome-spindle attachments during cell division. Nat Cell Biol. 2004, 6: 232-237.CrossRefPubMed
21.
Temme A, Rieger M, Reber F, Lindemann D, Weigle B, estelkoetter-Bachert P, Ehninger G, Tatsuka M, Terada Y, Rieber EP: Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell. 2003, 14: 78-92. 10.1091/mbc.E02-04-0182PubMedCentralCrossRefPubMed
22.
Delacour-Larose M, Molla A, Skoufias DA, Margolis RL, Dimitrov S: Distinct dynamics of Aurora B and Survivin during mitosis. Cell Cycle. 2004, 3: 1418-1426. 10.4161/cc.3.11.1203CrossRefPubMed
23.
Minoshima Y, Kawashima T, Hirose K, Tonozuka Y, Kawajiri A, Bao YC, Deng X, Tatsuka M, Narumiya S, May WS, Nosaka T, Semba K, Inoue T, Satoh T, Inagaki M, Kitamura T: Phosphorylation by aurora B converts MgcRacGAP to a RhoGAP during cytokinesis. Dev Cell. 2003, 4: 549-560. 10.1016/S1534-5807(03)00089-3CrossRefPubMed
24.
Temme A, Herzig E, Weigle B, Morgenroth A, Schmitz M, Kiessling A, Rieger MA, Schackert HK, Rieber EP: Inhibition of malignant glioma cell growth by a survivin mutant retrovirus. Hum Gene Ther. 2005, 16: 209-222. 10.1089/hum.2005.16.209CrossRefPubMed
25.
Kaur H, Bekier ME, Taylor WR: Regulation of Borealin by phosphorylation at serine 219. J Cell Biochem. 2010, 111: 1291-1298. 10.1002/jcb.22853CrossRefPubMed
26.
Hendruschk S, Wiedemuth R, Aigner A, Topfer K, Cartellieri M, Martin D, Kirsch M, Ikonomidou C, Schackert G, Temme A: RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol. 2011, 13: 1074-1089. 10.1093/neuonc/nor098PubMedCentralCrossRefPubMed
27.
Wang Z, Fukuda S, Pelus LM: Survivin regulates the p53 tumor suppressor gene family. Oncogene. 2004, 23: 8146-8153. 10.1038/sj.onc.1207992CrossRefPubMed
28.
Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC: Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem. 2004, 279: 2077-2084. 10.1074/jbc.M309479200CrossRefPubMed
29.
Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK, Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC, Mak TW: Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med. 2004, 199: 399-410.PubMedCentralCrossRefPubMed
30.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002, 277: 3247-3257. 10.1074/jbc.M106643200CrossRefPubMed
31.
Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002, 21: 2613-2622. 10.1038/sj.onc.1205353CrossRefPubMed
32.
Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002, 277: 5484-5489. 10.1074/jbc.M108302200CrossRefPubMed
33.
Paul R, Wollman R, Silkworth WT, Nardi IK, Cimini D, Mogilner A: Computer simulations predict that chromosome movements and rotations accelerate mitotic spindle assembly without compromising accuracy. Proc Natl Acad Sci USA. 2009, 106: 15708-15713. 10.1073/pnas.0908261106PubMedCentralCrossRefPubMed
34.
Guerrero AA, Martinez A, van Wely KH: Merotelic attachments and non-homologous end joining are the basis of chromosomal instability. Cell Div. 2010, 5: 13- 10.1186/1747-1028-5-13PubMedCentralCrossRefPubMed
35.
Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ: Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 2000, 97: 10389-10394. 10.1073/pnas.190030497PubMedCentralCrossRefPubMed
36.
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000, 287: 1824-1827. 10.1126/science.287.5459.1824CrossRefPubMed
37.
Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW: Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol. 1992, 12: 5041-5049.PubMedCentralCrossRefPubMed
38.
Ciosk R, Zachariae W, Michaelis C, Shevchenko A, Mann M, Nasmyth K: An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast. Cell. 1998, 93: 1067-1076. 10.1016/S0092-8674(00)81211-8CrossRefPubMed
39.
Glotzer M, Murray AW, Kirschner MW: Cyclin is degraded by the ubiquitin pathway. Nature. 1991, 349: 132-138. 10.1038/349132a0CrossRefPubMed
40.
Pinsky BA, Kung C, Shokat KM, Biggins S: The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol. 2006, 8: 78-83. 10.1038/ncb1341CrossRefPubMed
41.
Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC: Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003, 63: 7724-7732.PubMed
42.
Saito T, Hama S, Izumi H, Yamasaki F, Kajiwara Y, Matsuura S, Morishima K, Hidaka T, Shrestha P, Sugiyama K, Kurisu K: Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells. Br J Cancer. 2008, 98: 345-355. 10.1038/sj.bjc.6604160PubMedCentralCrossRefPubMed
43.
Yang D, Welm A, Bishop JM: Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA. 2004, 101: 15100-15105. 10.1073/pnas.0406665101PubMedCentralCrossRefPubMed
44.
Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H: Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene. 2004, 23: 6845-6853. 10.1038/sj.onc.1207860CrossRefPubMed
45.
Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 2004, 23: 7494-7506. 10.1038/sj.onc.1208049CrossRefPubMed
46.
Reichert S, Rodel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, Kaina B, Rodel F: Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol. 2011, 101: 51-58. 10.1016/j.radonc.2011.06.037CrossRefPubMed
47.
Capalbo G, Dittmann K, Weiss C, Reichert S, Hausmann E, Rodel C, Rodel F: Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int J Radiat Oncol Biol Phys. 2010, 77: 226-234. 10.1016/j.ijrobp.2009.12.001CrossRefPubMed
48.
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58: 5315-5320.PubMed
49.
Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, Osinaga E, Rabinovich GA, Rivarola VA: Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem. 2008, 105: 381-390. 10.1002/jcb.21836CrossRefPubMed
50.
Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC: Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest. 2001, 108: 991-999. 10.1172/JCI13345PubMedCentralCrossRefPubMed
51.
Zhang W, Hanks AN, Boucher K, Florell SR, Allen SM, Alexander A, Brash DE, Grossman D: UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis. 2005, 26: 249-257.PubMedCentralCrossRefPubMed
52.
LaCasse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998, 17: 3247-3259.CrossRefPubMed
53.
Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res. 1999, 248: 30-43. 10.1006/excr.1999.4455CrossRefPubMed
54.
Fukuda S, Mantel CR, Pelus LM: Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood. 2004, 103: 120-127. 10.1182/blood-2003-05-1756CrossRefPubMed
55.
Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005, 5: 773-785. 10.1038/nrc1714CrossRefPubMed
56.
Nguyen HG, Makitalo M, Yang D, Chinnappan D, St HC, Ravid K: Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J. 2009, 23: 2741-2748. 10.1096/fj.09-130963PubMedCentralCrossRefPubMed
57.
Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D: Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res. 2003, 63: 567-572.PubMed
58.
Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD: Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010, 24: 1920-1926. 10.1038/leu.2010.198PubMedCentralCrossRefPubMed
59.
Temme A, Geiger KD, Wiedemuth R, Conseur K, Pietsch T, Felsberg J, Reifenberger G, Tatsuka M, Hagel C, Westphal M, Berger H, Simon M, Weller M, Schackert G: Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. J Neuropathol Exp Neurol. 2010, 69: 632-642. 10.1097/NEN.0b013e3181e4c06eCrossRefPubMed
60.
Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002, 296: 550-553. 10.1126/science.1068999CrossRefPubMed
61.
Carlessi L, De FL, Lecis D, Vescovi A, Delia D: DNA-damage response, survival and differentiation in vitro of a human neural stem cell line in relation to ATM expression. Cell Death Differ. 2009, 16: 795-806. 10.1038/cdd.2009.10CrossRefPubMed
62.
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A: Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012, 9: 676-682. 10.1038/nmeth.2019CrossRefPubMed
63.
Schrock E, Veldman T, Padilla-Nash H, Ning Y, Spurbeck J, Jalal S, Shaffer LG, Papenhausen P, Kozma C, Phelan MC, Kjeldsen E, Schonberg SA, O'Brien P, Biesecker L, du Manoir S, Ried T: Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum Genet. 1997, 101: 255-262. 10.1007/s004390050626CrossRefPubMed
Metadata
Title
Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53
Authors
Ralf Wiedemuth
Barbara Klink
Katrin Töpfer
Evelin Schröck
Gabriele Schackert
Masaaki Tatsuka
Achim Temme
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-107

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer

Research

Chemoprevention of dietary digitoflavone on colitis-associated colon tumorigenesis through inducing Nrf2 signaling pathway and inhibition of inflammation

Research

Role of SIRT1 in regulation of epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis

Research

KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer

Research

Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis

Research

Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits